Related Experiment Video
Updated: Jan 30, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL)
1Department of Dermatology, University Hospital of Zurich, Switzerland. reinhard.dummer@usz.ch
Abstract:
Over the last 20 years the treatment of cutaneous T-cell lymphoma has been in a state of continual change. New therapies are constantly emerging as the search continues for more effective and tolerable disease-specific agents that satisfy medical needs. Therapies under investigation include topical retinoids, fusion molecules like denileukin diftitox, pegylated interferon, interleukin-2, and interleukin-12. Pegylated liposomal doxorubicin, gemcitabine, and chlorodeoxyadenosine also appear to have clinical potential. Other identified agents include vaccines and monoclonal antibodies. This article reviews some of the most recent clinical innovations.
Insights
New therapies for cutaneous T-cell lymphoma (CTCL) are evolving, with ongoing research into agents like topical retinoids and monoclonal antibodies to improve treatment effectiveness and tolerability.
Area of Science:
- Dermatology
- Oncology
- Immunology
Background:
- Cutaneous T-cell lymphoma (CTCL) treatment has significantly evolved over the past two decades.
- There is a continuous need for more effective and tolerable disease-specific therapies for CTCL.
Purpose of the Study:
- To review recent clinical innovations in the treatment of cutaneous T-cell lymphoma.
- To highlight emerging therapeutic agents and their potential clinical applications.
Main Methods:
- Review of recent clinical innovations and emerging therapies for CTCL.
- Identification of novel agents under investigation and those with clinical potential.
Main Results:
- Several novel therapeutic avenues are under investigation for CTCL.
- Agents including topical retinoids, denileukin diftitox, pegylated interferon, interleukins-2 and -12, pegylated liposomal doxorubicin, gemcitabine, and chlorodeoxyadenosine show promise.
- Vaccines and monoclonal antibodies are also identified as potential treatment options.
Conclusions:
- The landscape of CTCL treatment is dynamic, with numerous new therapies emerging.
- These innovations aim to address unmet medical needs by offering improved efficacy and tolerability.
- Further clinical investigation is warranted for these promising agents.
Related Concept Videos
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Social Cognitive Perspective on Personality
Criticisms of the Evolutionary Perspective
Evolutionary psychology provides one explanation for these findings, suggesting...
The Behavioral Perspective on Personality
Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Carl Rogers' Humanistic Perspective on Personality
The organism refers to an individual's inherent blueprint, which Rogers saw as innately positive and directed toward helping others, unlike Freud's view of the id as driven by base impulses. The self is a person's...

